Given the difficulty of experimental determination of drug-protein interactions, there is a significant motivation to develop effective in silico prediction methods that can provide both new predictions for experimental verification and supporting evidence for experimental results. Most recently, classification methods such as support vector machines (SVMs) have been applied to drug-target prediction. Unfortunately, these methods generally rely on measures of the maximum "local similarity" between two protein sequences, which could mask important drug-protein interaction information since drugs are much smaller molecules than proteins and drug-target binding regions must comprise only small local regions of the proteins. We therefore develop a novel sparse learning method that considers sets of short peptides. Our method integrates feature selection, multi-instance learning, and Gaussian kernelization into an L 1 norm support vector machine classifier. Experimental results show that it not only outperformed the previous methods but also pointed to an optimal subset of potential binding regions. Supplementary materials are available at "www.cs.ualberta.ca/~ys3/drug_target".
Introduction
Proteins operate in highly interconnected networks ("interactome networks") that play a central role in governing cell functions. If a protein's conformation is changed, its function can be altered, thus affecting cell function. Drugs are small molecules that bind to target proteins to intensionally change the protein conformation, ultimately achieving treatment effects. The function of many classes of pharmaceutically useful protein targets, such as enzymes, ion channels, G protein coupled receptors (GPCRs), and nuclear receptors, can be modulated by ligand interaction. Identifying interaction between ligands and proteins is therefore a key to genomic drug discovery.
Various high-throughput technologies for analyzing the genome, the transcriptome, and the proteome have enhanced our understanding of the space populated by protein classes. Meanwhile, the development of high-throughput screening technology has enabled broader exploration of the space of chemical compounds. [1] [2] [3] The goal of the chemical genomics research is to identify potentially useful compounds, such as imaging probes and drug leads, by relating the chemical space to the genomic space. Unfortunately, our understanding of the relationship between the chemical and the genomic spaces remains insufficient. For example, the PubChem database at NCBI 4 contains information of millions of chemical compounds, but the number of compounds with known target proteins is limited. The lack of documented protein-chemical interactions suggests that many remain to be discovered, which motivates Similarly for target-to-drug prediction, target-target similarities are first obtained using the primary amino acid sequences; 13, 17, 18 then for a new target with known primary sequence, its similarities to known targets are calculated to predict its interactions with known drugs again using the bipartite interaction graph.
It should be pointed out that in the state-of-the-art works of target-to-drug prediction, the target-target similarity is defined out of the normalized Smith-Waterman score. 17 This S-W score measures the maximum "local similarity" between two protein sequences, 19 thus reasonable, but the local similarity still uses the whole sequences and consequently might involve long substrings, which is unreasonable. In fact, long substrings could mask important interaction information, since drugs are usually much smaller molecules than proteins and the drug-target binding sites mostly comprise of only small local regions of the target.
In this work, we focus on the latter target-to-drug prediction to address the issues in the existing works. We first attempt to identify key local binding regions from the common short substrings shared by proteins that interact with the same drug. These key short substrings are then used to construct a vector representation for a protein sequence, to be used in the training and testing phases of a classifier. The use of key short substrings (i.e. potential binding regions) as features for the targets is a more direct and meaningful representation for drug interaction prediction. Additionally, the explicit vector representation of targets, as opposed to assessing similarity based on the S-W score, maps the targets into higher dimensional spaces, thus increasing the effectiveness of kernel-based classifiers. We remark that our use of common short substrings differ from the substring composition representation for proteins, 15 which uses all substrings while disregarding whether interactions exist.
The rest of the paper is organized as follows. In Section 2, we introduce the details of our prediction method, in which we focus on the SVM classifiers. We demonstrate in Section 3 the performance of our method compared against the existing ones. Lastly, in Section 4, we discuss the advantages and disadvantages of our method and propose future work.
Methods
The drug-target interaction prediction framework is the same as in Bleakley et al., 17 in which we assume a dataset containing m drugs d 1 , d 2 , . . . , d m and n targets t 1 , t 2 , . . . , t n , and the binary indicator on whether or not drug d i interacts target t j . The goal is to predict which of the drugs a new target t c will interact.
Target Vectorization
In the bipartite local model (BLM) by Bleakley et al., 17 to which our method will compare against, the similarity between two targets t and t ′ is defined as the normalized SmithWaterman score: 17
where SW (·, ·) denotes the original Smith-Waterman score. 19 As we mentioned in the introduction, such a similarity measure might overlook the key short sequence regions to which a drug binds. 
where L(·, ·) is length of the longest common substring between the two sequences and c s is the number of occurrence of substring s. Intuitively, if target t c contains a long substring that is also frequent in the binding targets, then its match score for this feature substring will be high indicating a high likelihood of binding. We use
This way we obtain an n × p training matrix X, where each row represents a training target, and a p × 1 testing vector x c representing the new target t c , along with the n × 1 binary training label vector y (with 1 indicating the target interacts with drug d i and −1 otherwise). The task is to construct a classifier to return 1 if the new target t c interacts with
The classification problem can be analogously formulated using set withoutSS substring set. Next we show how to construct a classifier from the training data.
Classification with Feature Selection
In any classification problem, the quality of features used determines the accuracy of predictions. Here, features correspond to substrings of target proteins, which comprise potential binding regions between the proteins and drugs. Thus, selecting good features not only improves classification accuracy, but also provides candidate drug-target binding sites for further investigation. We investigated an approach that integrates feature selection in L 1 -norm based support vector machine (SVM) classification method.
The primal form of L 1 -norm SVM is:
where △(y) denotes putting the vector y on the main diagonal of a square matrix. Here 
By introducing Lagrangian multipliers λ ≥ 0 and µ ≥ 0, (4) becomes
Let the objective function of (5) be L 1 , and let
Let the objective function of (6) be L 2 , and let ∂L2 ∂b = 0. We get λ T y = 0, so (6) becomes
Let the objective function of (7) be L 3 , and let
Note that γ is the feature selection vector. Crucially, this problem is convex in γ and has no local minima, 21 hence it provides an optimal form of feature selection that can be efficiently obtained in conjunction with SVM training. Because a drug may bind to different regions of different proteins, i.e., different regions on different targets can bind to the same drug, each positive data point may correspond to a different set of important features (substrings). Therefore, the nature of this drug-target classification problem is essentially a multi-instance classification problem. To address this, we consider two ideas:
Idea (a) Use a radial basis function (RBF) kernel (Gaussian kernel), rather than a linear kernel since this addresses the multi-instance classification problem more effectively after implicitly mapping data points to an infinite dimensional space. After Gaussian kernelization, the original linear kernel matrix Idea (a) can be easily applied to (8) at the sacrifice of convexity, while applying Idea (b) to (8) will introduce too many extra coefficients which makes the model computationally expensive. To circumvent these issues, we introduce an efficient approach to re-weight the features. Intuitively, we wish to down-weight the features that are false positive indicator of binding, i.e. features that have a high score/value at some negative training examples (not bind). This motivation is similar to the case in multi-instance learning, where false positive indicators call for more strict control than true positive indicators. Towards this end, we introduce a p-dimensional weight vector c corresponding to the p features, and re-scale the feature matrix X byX = X△(c). A simple formula of c that concretizes our intuition is Therefore by replacing X withX in (8), we encourage using features that indicate less false positive, and formally we obtain
where
. We solve (9) by using a combination of L-BFGS-B (Limited-memory Broyden-FletcherGoldfarb-Shanno Bounded Optimization) and gradient decent method over γ. After optimization, we get solutions for γ and λ. γ serves as a useful feature selector, with γ j > ϵ indicating the j's features should be selected and otherwise not. λ can be used to construct the hyperplane in the SVM and to predict new data points. Given a test data point (target) x c , we can predict its label (binding to the drug or not) based on the sign of the classifier's output:
As a key step for solving (9), we need the partial derivative of the objective function in (9) (denoted as L 4 ) with respect to the k's feature selector γ k :
Experimental Results and Discussion

Methods under Comparison
We compared our method with the state-of-the-art method proposed by Bleakley et al. 17 In particular, we focused on target-side prediction of their method to make the two approaches comparable. Bleakley et al. 17 used the normalized Smith-Waterman score in (1) to evaluate the similarity between two target sequences. In the context of SVM classification, they used this target-target similarity matrix as the kernel matrix, i.e. the kernel matrix was fixed in their method. Based on this similarity measure, nearest neighbor (NN) classifiers can also be constructed as a baseline. We refer to Bleakley et al.'s approach as BLM SVM and BLM NN respectively. On the other hand, our methods include:
• SS L1-SVM: L1-SVM with withSS feature (the main model of this paper),
• SS L1-SVM: the classic L2 norm SVM with withSS feature,
• SS NN FS: nearest neighbor classifier based on the features selected by SS L1-SVM,
• SS NN noFS: nearest neighbor classifier based on all withSS features.
Experiment Settings
The framework of our experiment is similar to Bleakley et al. 17 Specifically, we enumerated all pairs of drug d i and protein t in the whole data set. For each (d i , t) pair, we treated t as the single test example while the remaining proteins were used as training examples. To learn an L1 and L2 SVM, we chose the hyper-parameters (e.g. β and ϵ) by using three-fold cross validation on the training set, making sure that all the three folders contain at least one target that binds to the drug (i.e., at least one positive example). After the classification model was learned, we applied it to protein t in a way like (10) , and obtained a score y it that could be subsequently used to compute useful performance measures (see Section 3.4). All y it calculated by ranging over all drugs d i and target t in the data set constituted a drug-by-target score table.
We set the minimum length of a feature sub-sequence to 5 after trying all lengths from 4 to 12, noting that a too small cutoff generated excessively many features while a too big cutoff generated an insufficient number of features.
Datasets
We used drug-target interaction information from Bleakley et al., 17 which was collected from the KEGG BRITE, 2 BRENDA, 22 SuperTarget 23 and DrugBank 24 databases. In particular, we used three data sets-nuclear receptors, GPCRS, and ion channel-which have 54, 223, 210 drugs, 26, 95, 204 targets, and 90, 635, 1476 interactions, respectively. The three data sets used in this article are identical to those used in the state-of-the-art study, 17 which facilitates a fair comparison between the two methods. Since we only focused on target-side prediction, we did not require any drug structural or pharmacological information to obtain drug-drug similarity information. The amino acid sequences of the target proteins were obtained from the KEGG GENES database. 2 Table 1 . Evaluations of classification quality on Nuclear data set. The F-Measure, Precision, and Recall scores were obtained at the cutoff point where F-Measure was maximized for respective prediction methods. Table 2 . Evaluations of classification quality on GPCR data set. The F-Measure, Precision, and Recall scores were obtained at the cutoff point where F-Measure was maximized for respective prediction methods. Table 3 . Evaluations of classification quality on Ion data set. The F-Measure, Precision, and Recall scores were obtained at the cutoff point where F-Measure was maximized for respective prediction methods. in the Nuclear, GPCR, and Ion Channels datasets, respectively. The significant reduction in feature set size can not only make the classification more efficient and effective, it can also help biological practitioners to identify important features more accurately. We further investigated the prediction result generated by the SS L1-SVM method and the BLM SVM method. At the prediction cutoff where both methods attained their own maximum F-Measure score, there were 8, 127, and 78 true positive interactions that SS L1-SVM managed to identify but were missed by BLM SVM. This was in comparison to 7, 16, 52 true positives that were identified by BLM SVM but not by SS L1-SVM. False positive is another important measurement of a method. On the three datasets Nuclear, GPCR, and Ion Channels, SS L1-SVM generated 0, 73, and 139 false positive interactions, compared to 2, 85, 117 false positive interactions generated by BLM SVM.
Some interesting case studies are in order. On the Nuclear dataset, the two nearest neighbors of the target protein RORB (KEGG Homo sapiens protein ID "hsa6096") under the normalized Smith-Waterman score are RORA ("hsa6095") and RORC ("hsa6097"), with scores 0.578 and 0.458 respectively. RORB and RORC share a common interacting drug Tretinoin (KEGG drug ID "D00094") while RORB and RORA do not. According to the BLM method, RORB will be predicted to have no interaction with Tretinoin because its nearest neighbor RORA does not interact with Tretinoin. On the contrary, our method can correctly identify the interaction between RORB and Tretinoin because the withSS feature set based method can discover two important substrings "EVVLVRMCRA-N" and "N-TV-FEGKYGGM" that exist in both RORB and RORC. Therefore, although the overall match score between RORB and RORC is not the highest, their feature vectors (with respect to the two feature substrings) are the most similar.
On the GPCR dataset, the five nearest neighbors of the target protein CHRM1 (KEGG Homo sapiens protein ID "hsa1128") under the normalized Smith-Waterman scores are CHRM5 ("hsa1133"), CHRM3 ("hsa1131"), CHRM4 ("hsa1132"), CHRM2 ("hsa1129"), and HRH3 ("hsa11255"), with scores 0.4707, 0.4536, 0.4237, 0.4228, and 0.2446 respectively. Although CHRM1 is supposed to bind to drug Metoclopramide (KEGG drug ID "D00726"), none of its five nearest neighbors bind to this drug. In fact binding occurs only with the 6-th nearest neighbor, HRH2 ("hsa3274"), whose SW norm score with respect to CHRM1 is 0.2137. Therefore, the BLM methods can hardly predict that CHRM1 binds to Metoclopramide. In contrast, our method can correctly predict this interaction because the important substrings such as "KRTPRRAA", "Y-AKRTP-RAA-MI-L-W", and "NYFL-SLA-AD" are present in both CHRM1 and several proteins that bind to Metoclopramide, e.g., HTR1A ("hsa3350"), HTR1B ("hsa3351"), HTR1D ("hsa3352"), HTR1E ("hsa3354"), HTR1F ("hsa3355"), HTR2A ("hsa3356"), HTR2B ("hsa3357"), HTR2C("hsa3358"), HTR4("hsa3360"), HTR5A("hsa3361"), and HTR6("hsa3362"), which are all considered as faraway neighbors according to the SW norm scores.
The binding regions discovered by our computational model can also be found on the Ion dataset. To provide potential drug-target binding regions for further investigation, we produced all the important common substrings selected by the SS L1-SVM method, which are made available online at "http://www.cs.ualberta.ca/~ys3/drug_target".
Conclusions
In this article, we proposed a novel drug-target interaction prediction method based on potential drug-target binding regions. According to the evaluation metrics, the proposed method significantly outperformed the current state-of-the-art methods. More importantly, it identified a number of drug-target interactions that were missed by previous methods. We believe that the poor recall of previous methods is due to the use of a target kernel matrix based on Smith-Waterman score: a low overall similarity between two protein sequences does not mean they do not share common drug binding regions. This drawback was overcome in our approach by collecting a large number of candidate binding regions (i.e., common substrings) that subsequently played the primary role in interaction prediction. In addition, the use of an explicit vector representation, as opposed to implicit similarity measure, enabled the easy use of non-linear kernel expansions that were not possible for fixed kernel methods like BLM.
Besides the kernels based on substring feature vector, we believe the techniques of string kernel proposed in 25 could be useful in this problem. One straightforward benefit of using the string kernel is that it will automatically consider all substrings of a given sequence pair. It can also provide more intuitive understanding of substring-based sequence similarities than using Gaussian kernel. However, to employ the string kernel, one needs to customize the feature selection function into the model and to extend the non-gapped matching in string kernels.
We presented a feature selection method based on L 1 -norm SVM that could not only predict the binding relations more accurately, but also find important candidate binding regions (features). It integrated feature selection directly into L 1 -norm SVM and kernelized the optimization model. A drawback was that the sparse regularization term tended to select only a single feature from the candidate set. This is a well known problem with L 1 based regularization. 26 To avoid this limitation, we will investigate a combination of L 1 and L 2 norm regularizers, known as the elastic net, 26 which is generally more effective at group feature selection. Another possible extension is to adopt the OSCAR model, 27 which appears even more effective. We also discovered that the inference problem of drug-target interaction-in some cases-can be considered as a multi-instance learning problem. So we proposed using multiple feature selection vectors for each positive training example in theory and applied the feature cost vector to address the multi-instance problem in practice. We hypothesize that more advanced machine learning methods specifically tailored for multi-instance classification can further improve the accuracy of drug-target interaction prediction. Moreover, considering that protein 3D structures carry the essential binding information and an increasing amount of protein 3D structure is being made available (e.g., PSI Nature Structural Biology Knowledgebase 28 ), incorporating protein 3D information in the prediction model in addition to sequence information would lead to promising improvement.
